论文信息 - 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results - 字舞流文

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

B. Halmos | L. Paz-Ares | B. Cho | C. Zhou | W. Lim | M. Reck | B. Mookerjee | A. Atmaca | J. González-Larriba | Y. Goto | I. Demedts | M. C. Dols | B. Dharan | S. Baka | Z. Zhu | S. Portella